Profund Advisors LLC Purchases 6,182 Shares of Kymera Therapeutics, Inc. $KYMR

Profund Advisors LLC boosted its holdings in Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 70.0% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 15,013 shares of the company’s stock after buying an additional 6,182 shares during the period. Profund Advisors LLC’s holdings in Kymera Therapeutics were worth $850,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of KYMR. Commodore Capital LP bought a new position in shares of Kymera Therapeutics in the second quarter worth about $32,730,000. Federated Hermes Inc. purchased a new position in Kymera Therapeutics in the 3rd quarter worth approximately $31,622,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Kymera Therapeutics by 121.5% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares in the last quarter. Millennium Management LLC boosted its stake in Kymera Therapeutics by 340.4% in the 1st quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the period. Finally, Frontier Capital Management Co. LLC grew its holdings in Kymera Therapeutics by 272.7% during the 2nd quarter. Frontier Capital Management Co. LLC now owns 491,810 shares of the company’s stock valued at $21,463,000 after buying an additional 359,847 shares in the last quarter.

Insider Buying and Selling at Kymera Therapeutics

In related news, Director Bruce Booth sold 678 shares of the stock in a transaction on Friday, December 12th. The stock was sold at an average price of $91.04, for a total transaction of $61,725.12. Following the sale, the director owned 685,393 shares in the company, valued at approximately $62,398,178.72. This represents a 0.10% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Nello Mainolfi sold 30,000 shares of the firm’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $78.06, for a total value of $2,341,800.00. Following the completion of the sale, the chief executive officer owned 663,077 shares of the company’s stock, valued at approximately $51,759,790.62. This represents a 4.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 420,895 shares of company stock valued at $37,778,351. Corporate insiders own 16.01% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on KYMR. Piper Sandler restated an “overweight” rating and set a $125.00 target price (up previously from $98.00) on shares of Kymera Therapeutics in a research report on Tuesday, December 9th. HC Wainwright increased their price objective on shares of Kymera Therapeutics from $84.00 to $134.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Stifel Nicolaus set a $114.00 price objective on Kymera Therapeutics in a research report on Monday, December 8th. Bank of America lifted their target price on Kymera Therapeutics from $71.00 to $112.00 and gave the stock a “buy” rating in a report on Tuesday, December 9th. Finally, Barclays increased their price target on Kymera Therapeutics to $133.00 and gave the company an “overweight” rating in a research note on Tuesday, January 27th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Buy” and an average price target of $117.00.

Kymera Therapeutics Stock Up 3.5%

Kymera Therapeutics stock opened at $82.27 on Thursday. The company’s 50-day moving average price is $77.48 and its 200-day moving average price is $61.64. The company has a market cap of $5.92 billion, a PE ratio of -22.92 and a beta of 2.21. Kymera Therapeutics, Inc. has a twelve month low of $19.44 and a twelve month high of $103.00.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.